Real Life Data on OnabotulinumtoxinA for Treatment of Chronic Migraine in Pediatric Age.

Laura PapettiIlaria FrattaleFabiana UrsittiGiorgia SforzaGabriele MonteMichela Ada Noris FerilliSamuela TarantinoMartina Proietti ChecchiMassimiliano Valeriani

Published in: Journal of clinical medicine (2023)

The use of OBT-A in pediatric age can have benefits in terms of reduction in the frequency and intensity of headache episodes. Furthermore, treatment with OBT-A has an excellent safety profile. These data support the use of OBT-A in the treatment of childhood migraine.

Keyphrases

electronic health record
big data
young adults
childhood cancer
early life